Merrimack Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>MP</div>
MACK -- USA Stock  

USD 3.82  0.02  0.53%

Merrimack Pharmaceuticals Enterprise Value is decreasing as compared to previous years. The preceding year's Enterprise Value was reported at 21.24 Million. The current Invested Capital is estimated to increase to about 751.3 K, while Earnings before Tax are projected to decrease to (20.3 M). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will examine Merrimack Pharmaceuticals. What exactly are Merrimack Pharmaceuticals shareholders getting in September? Merrimack Pharmaceuticals odds of distress is over 75 percent. Will traders continue to be optimistic, or should we expect a sell-off in September?
Published over a month ago
View all stories for Merrimack Pharmaceuticals | View All Stories
Does Merrimack Pharmaceuticals (NASDAQ:MACK) have strong forward indicators based on the recent surge?
Merrimack Pharmaceuticals appears to be relatively risky, given 1 month investment horizon. Merrimack Pharmaceuticals has Sharpe Ratio of 0.11, which conveys that the firm had 0.11% of return per unit of risk over the last month. Our standpoint towards estimating the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Merrimack Pharmaceuticals, which you can use to evaluate future volatility of the firm. Please exercise Merrimack Pharmaceuticals Downside Deviation of 2.51, risk adjusted performance of 0.1527, and Mean Deviation of 2.52 to check out if our risk estimates are consistent with your expectations.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Merrimack Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Potential Merrimack Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Merrimack Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Merrimack Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Merrimack Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Merrimack Pharmaceuticals fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Merrimack Pharmaceuticals performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Merrimack Pharmaceuticals shares is the value that is considered the true value of the share. If the intrinsic value Merrimack is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Merrimack Pharmaceuticals. Please read more on our fundamental analysis page.

And What about dividends?

A dividend is the distribution of a portion of Merrimack Pharmaceuticals earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Merrimack Pharmaceuticals dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. Merrimack one year expected dividend income is about $0.67 per share.
Merrimack Pharmaceuticals Dividend Yield is decreasing as compared to previous years. The last year's value of Dividend Yield was reported at 0.57. The current Dividends per Basic Common Share is estimated to increase to 1.85, while Payment of Dividends and Other Cash Distributions is projected to decrease to (33.1 M).
Last ReportedProjected for 2020
Payment of Dividends and Other Cash Distributions-30.7 M-33.1 M
Dividend Yield 0.57  0.65 
Dividends per Basic Common Share 1.80  1.85 
Investing in stocks that pay dividends, such as stock of Merrimack Pharmaceuticals, is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Merrimack Pharmaceuticals must own a stock before its ex-dividend date to receive its next dividend. This type of analysis is very useful when you want to generate a past dividend schedule and payout information for Merrimack Pharmaceuticals. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.

How important is Merrimack Pharmaceuticals's Liquidity

Merrimack Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Merrimack Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Merrimack Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Merrimack Pharmaceuticals's total debt and its cash.

How Merrimack utilizes its cash?

To perform a cash flow analysis of Merrimack Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Merrimack Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Merrimack Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Merrimack Pharmaceuticals Net Cash Flow from Operations is decreasing as compared to previous years. The last year's value of Net Cash Flow from Operations was reported at (31.37 Million)

Merrimack Pharmaceuticals Gross Profit

Merrimack Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Merrimack Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Merrimack Pharmaceuticals Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Breaking down the case for Merrimack Pharmaceuticals

Institutional investor usually refers to an organization that invests money in Merrimack Pharmaceuticals on behalf of clients or other money managers. Buying and selling of large positions of Merrimack Pharmaceuticals stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Merrimack Pharmaceuticals stock. Let's take a look at how the ownership of Merrimack is distributed among investors.

Ownership Allocation

Merrimack Pharmaceuticals holds a total of 13.38 Million outstanding shares. Over half of Merrimack Pharmaceuticals outstanding shares are owned by institutional investors. These institutional investors are typically referred to corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Merrimack Pharmaceuticals. Please watch out for any change in the institutional holdings of Merrimack Pharmaceuticals as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
Retail Investors39.77

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Merrimack Pharmaceuticals has an asset utilization ratio of 121.84 percent. This signifies that the company is making $1.22 for each dollar of assets. An increasing asset utilization means that Merrimack Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
19.2 M
11 M
Current Assets19.18 Million60.7
Assets Non Current1.43 Million4.51
Goodwill11 Million34.79

Will Merrimack Pharmaceuticals growth be viable after the surge?

Recent total risk alpha indicator falls down to -0.32. Possible price growth? Merrimack Pharmaceuticals currently demonstrates below-verage downside deviation. It has Information Ratio of 0.01 and Jensen Alpha of 0.28. However, we do advice investors to further question Merrimack Pharmaceuticals expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Conclusion on Merrimack Pharmaceuticals

Although few other entities under the biotechnology industry are still a bit expensive, Merrimack Pharmaceuticals may offer a potential longer-term growth to traders. With a relatively neutral outlook on the recent economy, it is better to hold off any trading of Merrimack as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Merrimack Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Merrimack Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to